Cholesterol drug prevents heart attack and early mortality, which has just been discovered by drug makers and labeled as Praluent or alirocumab.
The new drug seems more successful in reducing the major risk of heart attack and premature death, as a concern with studying heart attack survivors, which can convince insurers to attempt the expensive treatment. However, research of new drug has been sponsored by the French multinational pharmaceutical company – Sanofi along with a biotechnology company – Regeneron Pharmaceuticals.
Co-chairman of the research and chief of cardiology, Dr. Philippe Gabriel Steg from the Bichat Hospital in Paris said in a statement during the ACC conference that, “We were really pleased to see the treatment was effective and associated with a reduction in mortality. It is remarkable that such a potent intervention is also so safe. Because the treatment effect was so much more marked in the patients with the highest LDL cholesterol, we believe that these patients are the optimal candidates for therapy.”
On Saturday, the findings of the research were disclosed during the conference held by the American College of Cardiology in Orlando, Florida. Since, the health experts have already been studying the bad cholesterol, lowering LDL and prevention of heart problems. Statins, also known as HMG-CoA reductase inhibitors are the important medicines for such conditions, while some people can’t get enough help or tolerate them.
Dr. Jeffrey Kuvin, ACC conference head and cardiology chief at the Dartmouth-Hitchcock Medical Center said that, “We need to reset our expectations and realize that benefits for any new drug are going to be fairly small when added to already good treatments such as statins.”